XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (Q3)Mar 31, 2021 | (FY)Dec 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | -77.14%126.18M | -64.28%740.32M | -41.56%552M | -40.64%2.07B | -43.32%944.49M | ---- | 52.15%3.49B | 120.34%1.67B | ---- | 10.55%2.29B |
Profit adjustment | ||||||||||
Interest (income) - adjustment | -21.68%-21.98M | -4.97%-37.42M | 21.07%-18.07M | 41.08%-35.64M | 23.13%-22.89M | ---- | -21.99%-60.49M | -93.10%-29.78M | ---- | -87.46%-49.59M |
Attributable subsidiary (profit) loss | 5.20%-50.02M | -18.74%-106.27M | -20.75%-52.76M | -23.97%-89.49M | -11.19%-43.69M | ---- | -57.87%-72.19M | -60.11%-39.29M | ---- | -30.35%-45.73M |
Impairment and provisions: | ---- | --41.29M | ---- | ---- | ---- | ---- | -150.02%-2.47M | -132.51%-1.12M | ---- | 429.90%4.93M |
-Impairment of trade receivables (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 354.05%3.8M |
-Impairment of goodwill | ---- | --41.29M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | ---- | -317.55%-2.47M | ---1.12M | ---- | --1.13M |
Revaluation surplus: | 177.10%11.28M | 56.69%-41.45M | 107.79%4.07M | 9.20%-95.69M | -597.90%-52.22M | ---- | -144.79%-105.39M | -132.54%-7.48M | ---- | 150.46%235.3M |
-Derivative financial instruments fair value (increase) | ---- | 105.41%3.88M | 107.25%3.88M | 27.25%-71.64M | -672.23%-53.5M | ---- | -143.16%-98.47M | 73.76%-6.93M | ---- | 94.82%228.14M |
-Other fair value changes | 5,773.96%11.28M | -88.44%-45.33M | -84.95%192K | -247.49%-24.05M | 329.91%1.28M | ---- | -196.69%-6.92M | -101.12%-555K | ---- | 130.92%7.16M |
Asset sale loss (gain): | 105.05%4.3M | -580.91%-67.35M | -1,589.64%-85.15M | 222.26%14.01M | 2,874.76%5.72M | ---- | 13.35%-11.46M | 98.98%-206K | ---- | 32.33%-13.22M |
-Loss (gain) from sale of subsidiary company | 108.30%7.96M | -16,667.26%-92.61M | ---95.88M | -96.92%559K | ---- | ---- | 90.57%18.15M | 456.00%10.8M | ---- | 224.23%9.53M |
-Loss (gain) on sale of property, machinery and equipment | -134.07%-3.66M | 87.86%25.26M | 87.70%10.73M | 149.11%13.45M | 151.92%5.72M | ---- | -20.36%-27.38M | 50.32%-11.01M | ---- | -1.21%-22.75M |
-Loss (gain) from selling other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---2.23M | ---- | ---- | ---- |
Depreciation and amortization: | -5.57%609.41M | 0.15%1.28B | 6.93%645.33M | 10.59%1.28B | 3.71%603.5M | ---- | 5.52%1.15B | 7.39%581.9M | ---- | 11.98%1.09B |
-Amortization of intangible assets | 15.68%59.78M | 10.82%111.8M | 3.01%51.68M | 28.35%100.89M | 39.00%50.17M | ---- | 28.94%78.6M | 18.39%36.09M | ---- | 36.89%60.96M |
Financial expense | -12.17%148.02M | 2.10%327.42M | 0.01%168.53M | -36.67%320.69M | -38.97%168.52M | ---- | -25.04%506.39M | -25.56%276.13M | ---- | -13.19%675.52M |
Exchange Loss (gain) | ---- | -105.41%-3.88M | -107.25%-3.88M | -27.25%71.64M | 672.23%53.5M | ---- | 143.16%98.47M | -73.76%6.93M | ---- | -94.82%-228.14M |
Special items | -173.13%-19.74M | -20.42%35.61M | 23.06%26.99M | 18.16%44.75M | 22.63%21.93M | ---- | 21.17%37.87M | 168.55%17.89M | ---- | 37.49%31.25M |
Operating profit before the change of operating capital | -34.73%807.44M | -39.47%2.17B | -26.31%1.24B | -28.93%3.58B | -32.07%1.68B | ---- | 25.94%5.04B | 51.09%2.47B | ---- | 6.70%4B |
Change of operating capital | ||||||||||
Inventory (increase) decrease | -17.40%386.7M | 128.78%156.39M | -12.11%468.17M | -161.79%-543.38M | 107.62%532.68M | ---- | -10.94%879.43M | 3.65%256.56M | ---- | 133.56%987.49M |
Accounts receivable (increase)decrease | -128.84%-290.44M | -22.76%693.32M | -49.64%1.01B | 144.39%897.65M | 25.53%2B | ---- | -496.63%-2.02B | 13.54%1.59B | ---- | 214.57%509.82M |
Accounts payable increase (decrease) | 9.93%-1.32B | -68.60%873.72M | -6,409.92%-1.47B | 245.81%2.78B | 102.22%23.23M | ---- | 170.38%804.56M | -320.54%-1.05B | ---- | -216.95%-1.14B |
Special items for working capital changes | 618.46%1.24B | 12.80%-1.56B | 125.95%172.84M | -280.58%-1.79B | -172.67%-666.13M | ---- | -40.31%990.19M | 1,043.66%916.62M | ---- | 540.61%1.66B |
Cash from business operations | -41.86%825.49M | -52.70%2.33B | -60.21%1.42B | -13.37%4.93B | -14.88%3.57B | ---- | -5.38%5.69B | 42.57%4.19B | ---- | 38.95%6.01B |
Other taxs | 60.59%-126.28M | 28.27%-498.91M | 22.99%-320.4M | -3.21%-695.5M | -13.97%-416.08M | ---- | -138.00%-673.87M | -128.16%-365.08M | ---- | -29.89%-283.13M |
Net cash from operations | -36.40%699.21M | -56.71%1.83B | -65.12%1.1B | -15.60%4.23B | -17.63%3.15B | -3.50%826M | -12.47%5.01B | 37.64%3.83B | --856M | 39.44%5.73B |
Cash flow from investment activities | ||||||||||
Interest received - investment | 21.68%21.98M | 5.13%37.47M | -21.07%18.07M | -41.37%35.64M | -23.90%22.89M | ---- | 20.66%60.79M | 77.19%30.08M | ---- | 109.99%50.38M |
Dividend received - investment | -37.34%25.8M | 168.99%66.95M | 154.23%41.17M | 69.03%24.89M | 9.98%16.19M | ---- | 11.59%14.72M | 33.29%14.72M | ---- | -43.76%13.2M |
Loan receivable (increase) decrease | -116.50%-5.46M | -391.70%-21.54M | -52.52%33.08M | -86.06%7.38M | 87.76%69.66M | ---- | 369.08%52.96M | 251.05%37.1M | ---- | -745.03%-19.68M |
Decrease in deposits (increase) | --0 | -846.64%-13.67M | ---- | -99.48%1.83M | ---- | ---- | 981.69%355.08M | 7.29%335.08M | ---- | 85.83%-40.27M |
Sale of fixed assets | 56.25%494.18M | -6.14%474.73M | 13.35%316.27M | 30.42%505.79M | 10.65%279.01M | ---- | -23.32%387.83M | 1.46%252.17M | ---- | 12.96%505.81M |
Purchase of fixed assets | 14.04%-680.06M | 10.19%-1.24B | -41.24%-791.1M | -32.76%-1.38B | -3.95%-560.12M | ---- | -10.17%-1.04B | -33.37%-538.82M | ---- | 44.73%-944.4M |
Purchase of intangible assets | -118.79%-144.69M | 55.02%-177.77M | 81.27%-66.13M | -540.81%-395.2M | -1,245.45%-352.99M | ---- | -30.06%-61.67M | -29.49%-26.24M | ---- | 7.78%-47.42M |
Sale of subsidiaries | -68.88%34.98M | 24,068.71%114.32M | --112.42M | -99.86%473K | ---- | ---- | 3,527.82%326.81M | -11,121.23%-23.37M | ---- | -182.34%-9.53M |
Acquisition of subsidiaries | 81.87%-789K | 85.46%-5.99M | 87.88%-4.35M | 93.82%-41.23M | 40.72%-35.91M | ---- | 21.27%-667.53M | 48.25%-60.57M | ---- | -26.75%-847.87M |
Recovery of cash from investments | -92.54%16.6M | 772.48%1.19B | --222.51M | -82.54%136.7M | ---- | ---- | 153.77%782.75M | 646.34%358.71M | ---- | 144.33%308.45M |
Cash on investment | 159.92%7.52M | -175.38%-965M | 67.51%-12.56M | 28.99%-350.42M | 85.96%-38.65M | ---- | 22.54%-493.47M | 19.03%-275.3M | ---- | -1,061.51%-637.03M |
Other items in the investment business | ---- | ---- | ---- | --126K | --126K | ---- | ---- | ---- | ---- | ---- |
Net cash from investment operations | -76.02%-229.94M | 63.00%-538.39M | 78.22%-130.63M | -415.76%-1.46B | -679.15%-599.78M | ---- | 83.09%-282.15M | 138.54%103.56M | ---- | 21.74%-1.67B |
Net cash before financing | -51.56%469.28M | -53.41%1.29B | -62.05%968.8M | -41.32%2.78B | -35.06%2.55B | ---- | 16.55%4.73B | 56.49%3.93B | ---- | 105.42%4.06B |
Cash flow from financing activities | ||||||||||
New borrowing | -10.02%9.98B | -8.89%24.28B | -7.43%11.09B | 10.88%26.65B | -13.72%11.98B | ---- | -20.95%24.03B | -0.64%13.88B | ---- | 1.96%30.4B |
Refund | 4.10%-10.54B | 14.99%-23.7B | 7.84%-10.99B | 0.48%-27.88B | 24.45%-11.92B | ---- | 15.94%-28.02B | -0.05%-15.78B | ---- | -23.71%-33.33B |
Issuing shares | ---- | ---- | ---- | -33.85%6.17M | -16.73%6.17M | ---- | -99.03%9.32M | -99.21%7.4M | ---- | 15,155.29%963.83M |
Issuance of bonds | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --470M |
Interest paid - financing | 21.70%-149.44M | -9.82%-349.11M | -6.32%-190.86M | 38.22%-317.9M | 37.27%-179.51M | ---- | 25.72%-514.56M | 6.86%-286.16M | ---- | 12.83%-692.72M |
Dividends paid - financing | 79.19%-132.86M | 21.35%-847.29M | 36.30%-638.6M | -60.28%-1.08B | -50.77%-1B | ---- | -21.60%-672.19M | -1,918.79%-664.93M | ---- | -17.42%-552.79M |
Absorb investment income | -87.48%100K | 824.79%10.82M | 277.56%799K | -94.84%1.17M | -106.44%-450K | ---- | 36.66%22.69M | --6.99M | ---- | 134.00%16.6M |
Issuance expenses and redemption of securities expenses | 90.56%-41.79M | -569.73%-468.96M | -4,020.68%-442.81M | 59.92%-70.02M | 89.37%-10.75M | ---- | -1,260.60%-174.72M | -711.15%-101.11M | ---- | 99.61%-12.84M |
Other items of the financing business | -34.18%14.22M | -57.23%38.33M | -61.26%21.61M | 203.75%89.61M | 311.32%55.78M | ---- | 65.23%-86.37M | -143.11%-26.4M | ---- | -2,991.00%-248.42M |
Net cash from financing operations | 22.15%-1.05B | 55.01%-1.28B | -10.25%-1.34B | 48.91%-2.84B | 60.66%-1.22B | ---- | -74.30%-5.56B | -271.27%-3.1B | ---- | -75.09%-3.19B |
Net Cash | -53.98%-576.23M | 123.67%15.28M | -128.04%-374.22M | 92.22%-64.55M | 59.89%1.33B | ---- | -195.41%-829.52M | -50.26%834.62M | ---- | 463.79%869.44M |
Begining period cash | 0.70%2.2B | -2.87%2.19B | -2.87%2.19B | -26.93%2.25B | -26.93%2.25B | ---- | 39.33%3.08B | 39.33%3.08B | ---- | 7.50%2.21B |
Cash at the end | -10.31%1.62B | 0.70%2.2B | -49.47%1.81B | -2.87%2.19B | -8.42%3.58B | ---- | -26.93%2.25B | 0.67%3.91B | ---- | 39.33%3.08B |
Cash balance analysis | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.